Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Categories: @vaccine-makers   

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Website: modernatx.com



Growth: Good revenue growth rate 13.7%, there is acceleration compared to average historical growth rates -17.5%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +35.7%

Profitability: LTM EBITDA margin is negative, -105.8%. On average the margin is decreasing steadily. Gross margin is high, +54.2%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.84 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -2.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 114.6% higher than minimum and 72.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -4.1x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $0.7 mln (-0.006% of cap.)

Key Financials (Download financials)

Ticker: MRNA
Share price, USD:  (0.0%)47.99
year average price 29.38  


year start price 32.60 2025-02-07

min close price 22.36 2025-11-20

max close price 51.87 2026-01-22

current price 47.99 2026-02-06
Common stocks: 397 760 005

Dividend Yield:  0.0%
EV / Sales: 3.3x
Margin (EBITDA LTM / Revenue): -105.8%
Fundamental value created in LTM:
Market Cap ($m): 19 089
Net Debt ($m): -1 180
EV (Enterprise Value): 17 909
Price to Book: 2.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-04globenewswire.com

Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.

2026-02-02zacks.com

Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know

2026-01-30accessnewswire.com

Dr. David Berman to Join Moderna as Chief Development Officer

2026-01-29globenewswire.com

RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA

2026-01-26zacks.com

Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know

2026-01-22youtube.com

Baseline characteristics in Moderna cancer vaccine 'misleading': Leerink's Dr. Mani Foroohar

2026-01-22zacks.com

MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data

2026-01-22youtube.com

Moderna is curbing investment in vaccine trials due to US backlash

2026-01-22reuters.com

Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV

2026-01-22forbes.com

What's Happening With Moderna Stock?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-01 2024-11-07 2024-08-01 2024-05-02 2023-11-03 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-11-06 16:05:25 2025-08-01 16:03:34 2025-02-21 07:11:05 2024-11-07 16:03:09 2024-08-01 16:02:28 2024-05-02 16:03:11 2024-02-23 16:03:10 2023-11-03 16:02:21 2023-08-03 16:04:10 2023-05-04 16:03:31 2023-02-24 16:03:35 2022-11-03 16:05:50 2022-02-25 08:07:15 2021-02-26 16:30:28
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 1 016M 142M 3 199M 1 855M 241M 167M 6 848M 1 831M 344M 1 862M 18 875M 3 220M 17 736M 803M
costOfRevenue 1 008M 119M 1 464M 514M 156M 132M 4 693M 2 241M 731M 792M 5 416M 1 100M 2 617M 39M
grossProfit 8M 23M 1 735M 1 341M 85M 35M 2 155M -410M -387M 1 070M 13 459M 2 120M 15 119M 764M
grossProfitRatio 0.008 0.162 0.723 0.353 0.21 -0.224 -1.125 0.575 0.658
researchAndDevelopmentExpenses 801M 700M 4 543M 1 137M 1 180M 1 027M 4 845M 1 160M 1 148M 1 131M 3 295M 820M 1 991M 1 370M
generalAndAdministrativeExpenses 0 0 1 028M 0 0 0 1 345M 0 0 0 1 011M 0 0 0
sellingAndMarketingExpenses 0 0 146M 0 0 0 204M 0 0 0 121M 0 0 0
sellingGeneralAndAdministrativeExpenses 268M 230M 1 174M 281M 268M 274M 1 549M 442M 332M 305M 1 132M 278M 567M 188M
otherExpenses -801M 0 -37M -7M -20M 2M 0 -51M 14M -48M -388M -144M -735M -31M
operatingExpenses 268M 930M 5 680M 1 411M 1 448M 1 301M 6 394M 1 602M 1 480M 1 436M 4 039M 954M 1 823M 1 527M
costAndExpenses 1 276M 1 049M 7 144M 1 925M 1 604M 1 433M 11 087M 3 843M 2 211M 2 228M 9 455M 2 054M 4 440M 1 567M
interestIncome 73M 81M 425M 103M 111M 120M 421M 105M 104M 109M 200M 58M 18M 25M
interestExpense 0 1 000 000 24M 6M 6M 6M 38M 10M 13M -61M 29M 8M 18M 10M
depreciationAndAmortization 52M 57M 189M 52M 41M 36M 621M 249M 92M 78M 348M 176M 232M 31M
ebitda -135M -760M -3 394M 79M -1 232M -1 230M -3 283M -1 763M -1 775M -288M 9 768M 1 342M 13 528M -703M
ebitdaratio -0.133 -5.352 0.043 -5.485 -7.365 -0.963 -5.16 -0.155 0.417
operatingIncome -260M -907M -3 945M -70M -1 363M -1 266M -4 239M -2 012M -1 867M -366M 9 420M 1 166M 13 296M -763M
operatingIncomeRatio -0.256 -6.387 -0.038 -5.656 -7.581 -1.099 -5.427 -0.197 0.362
totalOtherIncomeExpensesNet 73M 89M 338M 91M 84M 101M 297M -51M 14M 61M 155M 51M -11M 19M
incomeBeforeTax -187M -818M -3 607M 21M -1 279M -1 165M -3 942M -1 958M -1 749M -305M 9 575M 1 217M 13 285M -745M
incomeBeforeTaxRatio -0.184 -5.761 0.011 -5.307 -6.976 -1.069 -5.084 -0.164 0.378
incomeTaxExpense 13M 7M -46M 8M 0 10M 772M 1 672M -369M -384M 1 213M 174M 1 083M 3M
netIncome -200M -825M -3 561M 13M -1 279M -1 175M -4 714M -3 630M -1 380M 79M 8 362M 1 043M 12 202M -747M
netIncomeRatio -0.197 -5.81 0.007 -5.307 -7.036 -1.983 -4.012 0.042 0.324
eps -0.51 -2.13 -9.27 0.034 -3.33 -3.08 -12.34 -9.53 -3.62 0.2 21.26 2.67 30.31 -1.96
epsdiluted -0.51 -2.13 0.033 -3.33 -3.08 -9.53 -3.62 0.19 2.53
weightedAverageShsOut 390M 388M 384M 385M 384M 382M 382M 381M 381M 386M 394M 390M 403M 381M
weightedAverageShsOutDil 390M 388M 384M 399M 384M 382M 382M 381M 381M 405M 416M 412M 431M 381M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-23 2023-02-24 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 401M 383M 171M 0 15M
ebit -3 583M -3 904M 9 420M 13 296M -735M
nonOperatingIncomeExcludingInterest -362M -335M 0 0 -29M
netIncomeFromContinuingOperations -3 561M -4 714M 8 362M 12 202M -747M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -3 561M -4 714M 8 362M 12 202M -747M
epsDiluted -9.27 -12.34 20.1 28.29 -1.96

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-01 2024-11-07 2024-08-01 2024-05-02 2023-11-03 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-11-06 16:05:25 2025-08-01 16:03:34 2025-02-21 07:11:05 2024-11-07 16:03:09 2024-08-01 16:02:28 2024-05-02 16:03:11 2024-02-23 16:03:10 2023-11-03 16:02:21 2023-08-03 16:04:10 2023-05-04 16:03:31 2023-02-24 16:03:35 2022-11-03 16:05:50 2022-02-25 08:07:15 2021-02-26 16:30:28
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 132M 1 279M 1 927M 1 644M 2 478M 2 068M 2 907M 2 932M 3 801M 3 441M 3 205M 3 027M 6 848M 2 624M
shortTermInvestments 3 372M 3 852M 5 098M 5 223M 6 010M 6 472M 5 697M 4 641M 4 658M 5 482M 6 697M 5 321M 3 879M 1 984M
cashAndShortTermInvestments 4 505M 5 131M 7 025M 1 644M 8 488M 8 540M 8 604M 7 573M 8 459M 8 923M 9 902M 8 348M 10 727M 4 608M
netReceivables 1 394M 457M 592M 1 564M 163M 387M 1 081M 1 866M 232M 1 113M 1 685M 2 821M 3 323M 1 408M
inventory 332M 240M 117M 412M 399M 295M 202M 487M 715M 732M 949M 2 077M 1 441M 47M
otherCurrentAssets 367M 343M 58M 6 046M 611M 378M 88M 873M 1 193M 6 836M 44M 85M 26M 11M
totalCurrentAssets 6 598M 6 171M 8 099M 9 666M 9 661M 9 600M 10 325M 10 799M 10 599M 12 122M 13 431M 14 297M 16 071M 6 298M
propertyPlantEquipmentNet 2 864M 2 919M 2 955M 3 165M 2 971M 2 760M 2 658M 2 717M 2 410M 2 135M 2 139M 2 132M 1 383M 387M
goodwill 52M 52M 52M 52M 52M 52M 52M 52M 52M 52M 0 0 0 0
intangibleAssets 47M 48M 40M 41M 42M 43M 44M 45M 46M 48M 0 0 0 0
goodwillAndIntangibleAssets 99M 100M 92M 93M 94M 95M 96M 97M 98M 100M 0 0 0 0
longTermInvestments 2 252M 2 380M 2 508M 2 335M 2 357M 3 694M 4 743M 5 273M 6 105M 7 442M 8 360M 8 655M 6 843M 639M
taxAssets 81M 81M 81M 81M 81M 81M 81M -97M 1 480M 1 262M 982M 920M 326M 0
otherNonCurrentAssets 241M 359M 407M 463M 516M 499M 523M 661M 1 192M 1 064M 946M 52M 46M 13M
totalNonCurrentAssets 5 537M 5 839M 6 043M 6 137M 6 019M 7 129M 8 101M 8 651M 11 285M 12 003M 12 427M 11 759M 8 598M 1 039M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 12 135M 12 010M 14 142M 15 803M 15 680M 16 729M 18 426M 19 450M 21 884M 24 125M 25 858M 26 056M 24 669M 7 337M
accountPayables 267M 175M 405M 373M 279M 183M 520M 494M 310M 389M 487M 330M 302M 18M
shortTermDebt 48M 43M 0 0 32M 25M 0 56M 221M 181M 0 260M 0 0
taxPayables 0 0 3M 4M 7M 52M 63M 56M 47M 66M 48M 66M 876M 0
deferredRevenue 163M 218M 153M 379M 702M 559M 568M 1 372M 1 040M 1 219M 2 038M 4 002M 6 253M 3 867M
otherCurrentLiabilities 1 203M 1 136M 863M 1 445M 1 350M 1 613M 842M 2 463M 1 552M 1 710M 243M 2 215M 140M 99M
totalCurrentLiabilities 1 681M 1 572M 2 206M 2 201M 2 363M 2 380M 3 015M 4 385M 3 123M 3 499M 4 923M 6 807M 9 128M 4 389M
longTermDebt 686M 698M 0 1 304M 1 244M 1 212M 0 1 272M 947M 927M 0 1 001M 0 0
deferredRevenueNonCurrent 157M 65M 58M 0 95M 58M 83M 166M 692M 673M 673M 175M 615M 177M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 -58M 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 281M 276M 267M 371M 266M 320M 256M 172M 173M 163M 135M -3 335M 76M 3M
totalNonCurrentLiabilities 1 124M 1 039M 1 035M 1 675M 1 605M 1 532M 1 557M 1 610M 1 812M 1 763M 1 812M 1 257M 1 396M 387M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 734M 741M 747M 0 1 269M 1 212M 1 243M 1 272M 947M 927M 1 200M 1 261M 916M 237M
totalLiabilities 2 805M 2 611M 3 241M 3 876M 3 968M 3 912M 4 572M 5 995M 4 935M 5 262M 6 735M 8 064M 10 524M 4 776M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
retainedEarnings 8 049M 8 249M 10 045M 11 165M 11 152M 12 431M 13 606M 13 389M 17 019M 18 399M 18 320M 16 855M 9 958M -2 244M
accumulatedOtherComprehensiveIncomeLoss 27M 23M -10M 11M -71M -101M -123M -211M -263M -267M -370M -351M -24M 3M
othertotalStockholdersEquity 1 254M 1 127M 751M 631M 487M 277M 193M 731M 1 488M
totalStockholdersEquity 9 330M 9 399M 10 901M 11 927M 11 712M 12 817M 13 854M 13 455M 16 949M 18 863M 19 123M 17 992M 14 145M 2 561M
totalEquity 9 330M 9 399M 10 901M 11 927M 11 712M 12 817M 13 854M 13 455M 16 949M 18 863M 19 123M 17 992M 14 145M 2 561M
totalLiabilitiesAndStockholdersEquity 12 135M 12 010M 15 803M 15 680M 16 729M 19 450M 21 884M 24 125M 26 056M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 12 135M 12 010M 14 142M 15 803M 15 680M 16 729M 18 426M 19 450M 21 884M 24 125M 25 858M 26 056M 24 669M 7 337M
totalInvestments 5 624M 6 232M 7 606M 7 581M 8 367M 10 166M 10 440M 5 273M 6 105M 7 442M 15 057M 13 976M 10 722M 2 623M
totalDebt 734M 741M 747M 1 355M 617M 1 237M 1 243M 1 272M 947M 927M 1 200M 1 261M 916M 237M
netDebt -399M -538M -1 180M -289M -2 478M -831M -1 664M -1 660M -2 854M -2 514M -2 005M -1 766M -5 932M -2 387M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-23 2023-02-24 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 358M 892M 1 385M 3 175M 1 391M
otherReceivables 234M 189M 300M 148M 20M
prepaids 307M 350M 851M 554M 224M
totalPayables 408M 583M 535M 1 178M 18M
otherPayables 3M 63M 48M 876M 0
accruedExpenses 745M 997M 1 911M 1 346M 375M
capitalLeaseObligationsCurrent 37M 25M 196M 211M 30M
capitalLeaseObligationsNonCurrent 710M 1 218M 1 004M 705M 207M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 866M 371M 1 173M 4 211M 4 802M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-01 2024-11-07 2024-08-01 2024-05-02 2023-11-03 2023-08-03 2023-05-04 2022-11-03
acceptedDate 2025-11-06 16:05:25 2025-08-01 16:03:34 2025-02-21 07:11:05 2024-11-07 16:03:09 2024-08-01 16:02:28 2024-05-02 16:03:11 2024-02-23 16:03:10 2023-11-03 16:02:21 2023-08-03 16:04:10 2023-05-04 16:03:31 2023-02-24 16:03:35 2022-11-03 16:05:50 2022-02-25 08:07:15 2021-02-26 16:30:28
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -200M -825M -3 561M 13M -1 279M -1 175M -4 714M -3 630M -1 380M 79M 8 362M 1 043M 12 202M -747M
depreciationAndAmortization 0 57M 189M 52M 41M 36M 621M 249M 92M 78M 348M 113M 232M 93M
deferredIncomeTax 0 0 0 0 0 0 828M 1 464M -220M -310M -559M 0 -318M 10M
stockBasedCompensation 0 130M 429M 112M 112M 101M 305M 77M 74M 75M 226M 70M 142M 93M
changeInWorkingCapital -818M -297M -78M 86M -146M 60M -139M 182M 574M -1 144M -3 455M -1 001M 1 308M 2 577M
accountsReceivables -1 013M 30M 534M -1 401M -26M 755M 493M -1 634M 881M 272M 1 790M -4M -1 784M -1 385M
inventory -91M -114M 83M -11M -104M -93M 747M 228M 18M 216M 492M -156M -1 394M -47M
accountsPayables 89M -47M -69M 96M 104M -303M 13M 179M -70M -117M 240M 145M 204M 12M
otherWorkingCapital 197M -166M -626M 1 402M -120M -299M -1 392M 1 409M -255M -1 515M -5 977M -986M 4 282M 3 997M
otherNonCashItems 171M 16M 17M -1 829M -2M -197M -19M 58M -55M -3M 59M 27M 54M 558 000
netCashProvidedByOperatingActivities -847M -919M -3 004M -1 566M -1 274M -989M -3 118M -1 600M -915M -1 225M 4 981M 252M 13 620M 2 027M
investmentsInPropertyPlantAndEquipment -33M -3M -1 051M -151M -182M -196M -707M -140M -234M -113M -400M -89M -284M -67M
acquisitionsNet 0 0 0 0 0 0 -85M -929M -2 178M -85M 0 0 0 0
purchasesOfInvestments -1 162M -1 295M -6 529M -1 251M -846M -2 544M -3 783M -816M -196M -1 108M -11 435M -191M -12 652M -2 956M
salesMaturitiesOfInvestments 1 895M 1 862M 9 529M 2 123M 2 677M 2 858M 8 781M 1 745M 2 374M 3 317M 6 699M 1 225M 4 443M 1 352M
otherInvestingActivites 0 0 0 0 314M 929M 2 178M 0 0
netCashUsedForInvestingActivites 700M 564M 721M 1 649M 118M 789M 1 944M 2 011M 945M
debtRepayment -3M -5M 3M 2M -1 000 000 -65M -56M 0 0
commonStockIssued 2M 14M 8M 32M 15M 6M 16M 9M 0
commonStockRepurchased 0 0 0 0 0 0 -1 153M 1 000 000 -628M -526M -3 329M -1 006M -857M 0
dividendsPaid 0 0 0 0 0 0 -40M 0 0
otherFinancingActivites 0 0 0 0 15M 59M 40M -25M -35M
netCashUsedProvidedByFinancingActivities -1 000 000 9M 11M 34M 14M -58M -668M -542M -1 041M
effectOfForexChangesOnCash 0 1 000 000 0 1 000 000 0 0 0 0 0 0 0 0 0 0
netChangeInCash -148M -345M -999M -831M 410M -856M -289M -869M 361M 244M -3 643M 156M 4 224M 2 388M
cashAtEndOfPeriod 1 132M 1 281M 1 929M 1 647M 2 478M 2 068M 2 928M 2 953M 3 822M 3 461M 3 217M 3 041M 6 860M 2 636M
cashAtBeginningOfPeriod 1 280M 1 626M 2 928M 2 480M 2 068M 2 924M 3 217M 3 822M 3 461M 3 217M 6 860M 2 885M 2 636M 248M
operatingCashFlow -847M -919M -3 004M -1 566M -1 274M -989M -3 118M -1 600M -915M -1 225M 4 981M 252M 13 620M 2 027M
capitalExpenditure -33M -3M -1 051M -151M -182M -196M -707M -140M -234M -113M -400M -89M -284M -67M
freeCashFlow -880M -922M -4 055M -1 717M -1 456M -1 185M -3 825M -1 740M -1 149M -1 338M 4 581M 163M 13 336M 1 960M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-21 2024-02-23 2023-02-24 2022-02-25 2021-02-26
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 -40M -30M 0
netCashProvidedByInvestingActivities 1 949M 4 206M -5 176M -8 523M -1 672M
netDebtIssuance -10M -270M -184M -140M -6M
longTermNetDebtIssuance -10M -270M -184M -140M -6M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 66M -1 107M -3 264M -733M 2 039M
netCommonStockIssuance 66M -1 107M -3 264M -733M 2 039M
commonStockIssuance 66M 46M 65M 124M 2 039M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 0 0 0 0 193 000
netCashProvidedByFinancingActivities 56M -1 377M -3 448M -873M 2 033M
incomeTaxesPaid 197M 0 2 729M 480M 1 000 000
interestPaid 24M 39M 25M 14M 9M

Earning call transcript

2025 q3
2025-11-06 ET (fiscal 2025 q3)
2025 q2
2025-08-01 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-14 ET (fiscal 2024 q4)
2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-01-12 12:01 ET
Moderna published news for 2025 q4
SEC form 8
2026-01-12 12:01 ET
Moderna published news for 2025 q4
SEC form 8
2026-01-05 14:04 ET
Moderna published news for 2025 q4
SEC form 8
2026-01-05 14:04 ET
Moderna published news for 2025 q4
SEC form 8
2025-11-20 07:12 ET
Moderna published news for 2025 q3
SEC form 8
2025-11-20 07:12 ET
Moderna published news for 2025 q3
SEC form 10
2025-11-06 21:05 ET
Moderna reported for 2025 q3
SEC form 8
2025-11-06 12:03 ET
Moderna published news for 2025 q3
SEC form 8
2025-11-06 12:03 ET
Moderna reported for 2025 q3
SEC form 10
2025-08-01 16:03 ET
Moderna reported for 2025 q2
SEC form 8
2025-08-01 07:02 ET
Moderna published news for 2025 q2
SEC form 8
2025-08-01 07:02 ET
Moderna reported for 2025 q2
SEC form 10
2025-05-01 20:02 ET
Moderna published news for 2025 q1
SEC form 8
2025-05-01 10:31 ET
Moderna published news for 2025 q1
SEC form 8
2025-05-01 10:31 ET
Moderna reported for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Moderna published news for 2025 q1
SEC form 10
2025-02-21 12:11 ET
Moderna published news for 2024 q4
SEC form 10
2025-02-21 00:00 ET
Moderna published news for 2024 q4
SEC form 8
2025-02-14 06:30 ET
Moderna published news for 2024 q4
SEC form 8
2025-02-14 06:30 ET
Moderna reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Moderna published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Moderna published news for 2024 q4
SEC form 10
2024-11-07 16:03 ET
Moderna reported for 2024 q3
SEC form 8
2024-11-07 06:33 ET
Moderna published news for 2024 q3
SEC form 8
2024-11-07 06:33 ET
Moderna reported for 2024 q3
SEC form 10
2024-08-01 16:02 ET
Moderna reported for 2024 q2
SEC form 8
2024-08-01 06:31 ET
Moderna published news for 2024 q2
SEC form 8
2024-08-01 06:31 ET
Moderna reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Moderna reported for 2024 q2
SEC form 10
2024-05-02 16:03 ET
Moderna published news for 2024 q1
SEC form 8
2024-05-02 06:31 ET
Moderna published news for 2024 q1
SEC form 8
2024-05-02 06:31 ET
Moderna reported for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Moderna published news for 2024 q1
SEC form 10
2024-02-23 16:03 ET
Moderna published news for 2023 q4
SEC form 10
2024-02-23 00:00 ET
Moderna published news for 2023 q4
SEC form 8
2024-02-22 06:32 ET
Moderna published news for 2023 q4
SEC form 8
2024-02-22 06:32 ET
Moderna reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Moderna published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Moderna published news for 2023 q4
SEC form 10
2023-11-03 16:02 ET
Moderna reported for 2023 q3
SEC form 10
2023-11-03 00:00 ET
Moderna reported for 2023 q3
SEC form 8
2023-11-02 06:33 ET
Moderna reported for 2023 q3
SEC form 10
2023-08-03 16:04 ET
Moderna reported for 2023 q2
SEC form 6
2023-08-03 06:33 ET
Moderna reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Moderna reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Moderna reported for 2023 q2
SEC form 10
2023-05-04 00:00 ET
Moderna published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Moderna published news for 2023 q1
SEC form 10
2023-02-24 16:03 ET
Moderna reported for 2022 q4
SEC form 10
2023-02-24 00:00 ET
Moderna reported for 2022 q4
SEC form 6
2023-02-23 07:03 ET
Moderna published news for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Moderna reported for 2022 q4
SEC form 6
2023-01-09 07:03 ET
Moderna published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Moderna published news for 2022 q4
SEC form 6
2023-01-03 07:05 ET
Moderna published news for 2022 q4
SEC form 6
2022-12-13 07:06 ET
Moderna published news for 2022 q3
SEC form 10
2022-11-03 16:05 ET
Moderna reported for 2022 q3
SEC form 6
2022-11-03 07:04 ET
Moderna published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Moderna reported for 2022 q3
SEC form 6
2022-09-29 08:08 ET
Moderna published news for 2022 q2
SEC form 6
2022-08-17 16:25 ET
Moderna published news for 2022 q2
SEC form 10
2022-08-03 16:01 ET
Moderna reported for 2022 q2
SEC form 6
2022-08-03 07:04 ET
Moderna published news for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Moderna reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Moderna reported for 2022 q2
SEC form 6
2022-06-01 16:31 ET
Moderna published news for 2022 q1
SEC form 6
2022-05-24 08:01 ET
Moderna published news for 2022 q1
SEC form 6
2022-05-13 16:05 ET
Moderna published news for 2022 q1
SEC form 6
2022-05-11 08:01 ET
Moderna published news for 2022 q1
SEC form 10
2022-05-04 16:07 ET
Moderna reported for 2022 q1
SEC form 6
2022-05-04 06:58 ET
Moderna published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Moderna reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Moderna reported for 2022 q1
SEC form 6
2022-05-03 16:36 ET
Moderna published news for 2022 q1
SEC form 6
2022-04-11 09:10 ET
Moderna published news for 2022 q1
SEC form 6
2022-03-09 16:16 ET
Moderna published news for 2021 q4
SEC form 10
2022-02-25 08:07 ET
Moderna published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
Moderna published news for 2021 q4
SEC form 6
2022-02-24 07:16 ET
Moderna published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Moderna published news for 2021 q4
SEC form 6
2022-01-10 07:22 ET
Moderna published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Moderna published news for 2021 q4
SEC form 6
2022-01-04 08:00 ET
Moderna published news for 2021 q4
SEC form 8
2022-01-04 00:00 ET
Moderna published news for 2021 q4
SEC form 10
2021-11-04 16:48 ET
Moderna published news for 2021 q3
SEC form 6
2021-11-04 07:04 ET
Moderna published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Moderna published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Moderna published news for 2021 q3
SEC form 10
2021-08-05 16:14 ET
Moderna published news for 2021 q2
SEC form 6
2021-08-05 06:42 ET
Moderna published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Moderna published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Moderna published news for 2021 q2
SEC form 10
2021-05-06 16:30 ET
Moderna published news for 2021 q1
SEC form 6
2021-05-06 07:29 ET
Moderna published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Moderna published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Moderna published news for 2021 q1
SEC form 6
2021-04-29 16:17 ET
Moderna published news for 2021 q1
SEC form 6
2021-04-28 07:33 ET
Moderna published news for 2021 q1
SEC form 6
2021-04-13 17:28 ET
Moderna published news for 2021 q1
SEC form 6
2021-04-13 10:41 ET
Moderna published news for 2021 q1
SEC form 8
2021-04-13 00:00 ET
Moderna published news for 2021 q1
SEC form 6
2021-03-10 16:39 ET
Moderna published news for 2020 q4
SEC form 6
2021-03-10 16:31 ET
Moderna published news for 2020 q4
SEC form 10
2021-02-26 16:30 ET
Moderna published news for 2020 q4
SEC form 6
2021-02-25 07:07 ET
Moderna published news for 2020 q4
SEC form 6
2021-01-04 08:06 ET
Moderna published news for 2020 q4
SEC form 6
2020-12-23 07:48 ET
Moderna published news for 2020 q3
SEC form 6
2020-12-21 07:03 ET
Moderna published news for 2020 q3
SEC form 6
2020-12-11 16:40 ET
Moderna published news for 2020 q3
SEC form 6
2020-11-30 07:04 ET
Moderna published news for 2020 q3
SEC form 6
2020-11-16 07:01 ET
Moderna published news for 2020 q3
SEC form 10
2020-10-30 08:24 ET
Moderna published news for 2020 q3
SEC form 6
2020-10-29 07:07 ET
Moderna published news for 2020 q3